As expected, these two HDAC inhibitors suppressed breast cancer cell proliferation independent of breast tumor subtype, with IC50 values ranging from 1 μM to 20 μM for SAHA and 30–200 nM for LBH589 (Fig. 1a and Supplementary Fig. 1a). Here, HDAC9 is linked to breast cancer.